Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results

Rexahn Pharmaceuticals (NYSE:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the year ended December 31, 2017.

As quoted in the press release:

“We continue to make significant progress in the development of our product candidates,” said Peter D. Suzdak, Ph.D., chief executive officer of Rexahn. “In 2017, we advanced RX-5902 into a Phase 2a trial in triple negative breast cancer and initiated a Phase 2a trial of RX-3117 in patients newly diagnosed with metastatic pancreatic cancer. Importantly, data presented last year demonstrated that RX-5902 enhanced the efficacy of immunotherapy agents in multiple preclinical models. In addition, we recently extended the intellectual property position on RX-3117 and RX-5902 and strengthened our leadership team. We also announced a collaboration to advance RX-0201 using non-dilutive capital through a proof of concept trial in hepatocellular carcinoma.”

Click here to read the full press release.